|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The expert consensus guideline series:adherence problems in patients with serious and persistent mental illness显示文摘 | Velligan D I Weiden P J Sajatovic M | 2009 | Clin Psychiatry2009，70，4： | 1 |
| 2 | Defining and assessing adherence to oral antipsychotics: a review of the literature 显示文摘 | Velligan DI Lain YW Glahn DC | 2006 | Schizophr Bull2006，32，： | 1 |
| 3 | Defining and assessing adherence to oral antipchotics:a review of the literature显示文摘 | Velligan DI Lam YW Glahn DC | | 0，，4： | 1 |
| 4 | DnaK-mediated alterations in human growth hormone protein inclusion bodies显示文摘 | Blum P Velligan M Lin N | 1992 | Biotechnology1992，10，： | 1 |
| 5 | Defining and assessing ad- herence to oral antipsychotics a review of the literature 显示文摘 | Velligan DI Lam YW Glahn DC etal | 2006 | Schizophr Bull2006，32，： | 1 |
| 6 | Executive function in schizophrenia显示文摘 | Velligan D I Bow-Thomas C C | 1999 | Semin Clin Neuropsychiatry1999，4，1： | 1 |
| 7 | Conceptualization and treatment of negative symptoms in schizophrenia显示文摘Negative symptoms of schizophrenia including social withdrawal, diminished affective response, lack of interest, poor social drive, and decreased sense of purpose or goal directed activity predict poor functional outcomes for patients with schizophrenia. They may develop and be maintained as a result of structural and functional brain abnormalities, particularly associated with dopamine reward pathways and by environmental and psychosocial factors such as self-defeating cognitions and the relief from overstimulation that accompanies withdrawal from social and role functioning. Negative symptoms are more difficult to treat than the positive symptoms of schizophrenia and represent an unmet therapeutic need for large numbers of patients with schizophrenia. While antipsychotic medications to treat the symptoms of schizophrenia have been around for decades, they have done little to address the significant functional impairments in the disorder that are associated with negative symptoms. Negative symptoms and the resulting loss in productivity are responsible for much of the world-wide personal and economic burden of schizophrenia. Pharmacologic treatments may be somewhat successful in treating secondary causes of negative symptoms, such as antipsychotic side effects and depression. However, in the United States there are no currently approved treatments for severe and persistent negative symptoms(PNS) that are not responsive to treatments for secondary causes. Pharmacotherapy and psychosocial treatments are currently being developed and tested with severe and PNS as their primary targets. Academia, clinicians, the pharmaceutical industry, research funders, payers and regulators will need to work together to pursue novel treatments to address this major public health issue. | Sonali Sarkar Kiley Hillner Dawn I Velligan | 2015 | World Journal of Psychiatry2015，5，4： | 1 |
| 8 | Executive function in schizophrenia 显示文摘 | Velligan DI Bow-Thomas CC | 1999 | Semin Clin Neuropsychiatry1999，4，1： | 1 |
| 9 | Cognitive behavior therapy for psychosis: Where have we been and where are we going? 显示文摘 | Velligan DI | 2009 | Schizophr Bull2009，35，5： | 1 |
| 10 | Cognitive dysfunction in schizophrenia and its importance to outcome:the place of atypical antipsychotics in treatment显示文摘 | Velligan DI Miller AL | 1999 | J Clin Psychiatry1999，60，23： | 1 |
| 11 | Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment显示文摘 | Velligan DT Miller AL | 1999 | Clin Psychiatry1999，，： | 1 |
| 12 | Defining and assessing adherence to oral an tipsychotics a review of the literature 显示文摘 | Velligan D I Lain Y W Glahn D C | 2006 | Schizophr Bull2006，32，4： | 1 |
| 13 | Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment显示文摘 | Velligan D Malla A | 1999 | Journal of Clinical Psychiatry1999，60，： | 1 |
| 14 | Measurement of psychiatric treatment adherence显示文摘 | Sajatovic M Velligan DI Weiden PJ | | 0，，6： | 1 |
| 15 | Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment显示文摘 | Velligan D Malla A | 1999 | Journal of Clinical Psychiatry1999，60，： | 1 |
| 16 | The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia显示文摘 | Velligan DI Diamond PM Mintz J | | 0，，3： | 1 |
| 17 | Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization显示文摘 | Velligan DI Miller AL | 1999 | Psychiatry Res1999，86，2： | 1 |
| 18 | A Randomized Controlled Trial Comparing Cognitive Behavior Therapy, Cognitive Adapta- tion Training, Their Combination and Treatment as Usual in Chronic Schizophrenia显示文摘 | Velligan DI Tai S Roberts DL | 2015 | Schizophrenia Bulletin2015，41，3： | 1 |
| 19 | Brief Psychiatric Rating Scale Expanded Version: How do new items affect factor structure 显示文摘 | Velligan D Prihoda T Dennehy E | 2005 | Psychiatry Res2005，135，3： | 1 |
| 20 | Gognitive Rehabilitation for Schizophrenia and the putative Role of Motivation and Expectancies 显示文摘 | Velligan DI KEM RS gold JM | 2006 | Schizophr Bull2006，32，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员